Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024.

Discover how modern immunotherapy awakens T cells to shrink melanoma tumors, tracked by PET scans and used after surgery to prevent relapse. In this segment, Dr. Morrison provides clinical context ...

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

Objective and design: The use of proton pump inhibitors in acid-related diseases such as peptic ulcer or erosive reflux oesophagitis is well established. The aim of the current nationwide, multicentre ...

In the new subcutaneous drug delivery landscape, the growing trend towards patient-friendly, at-home administration is ...